{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:02:34Z","timestamp":1794049354292,"version":"4.8.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A new circulating biomarker superior to carbohydrate antigen 19\u20139 (CA19-9) is needed for diagnosing pancreatobiliary cancer (PBca). The aim of this study was to identify serum microRNA (miRNA) signatures comprising reproducible and disease-related miRNAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This multicenter study involved patients with treatment-na\u00efve PBca and healthy participants. The optimized serum processing conditions were evaluated using\n                      <jats:italic>t<\/jats:italic>\n                      -distributed stochastic neighbor embedding (\n                      <jats:italic>t<\/jats:italic>\n                      -SNE) visualization. Serum miRNA candidates for disease association were selected using weighted gene coexpression network analysis (WGCNA). A miRNA signature combining multiple serum miRNAs was tested in exploratory, validation, and independent validation sets. The synthesis and secretion of diagnostic miRNAs were evaluated using human pancreatic cancer cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 284 (150 healthy and 134 PBca) of 827 serum samples were processed within 2\u00a0h of blood collection before freezing, distributed in the same area as that in the\n                      <jats:italic>t<\/jats:italic>\n                      -SNE map, and assigned to an exploratory set. The 193 optimized samples were assigned to either the validation (50 healthy, 47 PBca) or independent validation (50 healthy, 46 PBca) set. Index-1, a combination of five serum miRNAs (hsa-miR-1343-5p, hsa-miR-4632-5p, hsa-miR-4665-5p, hsa-miR-665, and hsa-miR-6803-5p) with disease association in WGCNA, showed a sensitivity and specificity of\u2009&gt;\u200980% and an AUC outperforming that of CA19-9 in the exploratory, validation, and independent validation sets. The AUC of Index-1 was superior to that of CA19-9 (0.856 vs. 0.649,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.038) for detecting T1 tumors. miR-665, a component of Index-1, was expressed in human pancreatic cancer cells, and its transfection inhibited cell growth.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The serum miRNA signature Index-1 is useful for detecting PBca and could facilitate the early diagnosis of PBca. These findings can help improve clinical PBca detection by providing an optimized biomarker that overcomes the limitations of the current standard.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-025-03849-x","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T09:19:26Z","timestamp":1737451166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Robust circulating microRNA signature for the diagnosis and early detection of pancreatobiliary cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Shuichi","family":"Mitsunaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuya","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamichi","family":"Kuwahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Iwama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuro","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"3849_CR1","unstructured":"National Cancer Center. Cancer registry and statistics. Cancer Information Service, National Cancer Center. http:\/\/ganjoho.jp\/public\/statistics\/pub\/statistics01.html. Accessed 27 Sep 2023. [Japanese]."},{"key":"3849_CR2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.critrevonc.2006.02.004","volume":"58","author":"A Mancuso","year":"2006","unstructured":"Mancuso A, Calabr\u00f2 F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol. 2006;58:231\u201341.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3849_CR3","unstructured":"Mitsunaga S. Transition of patient background and treatment outcomes for bile duct cancer \u2013 a study of 1031 cases at the National Cancer Center East Hospital. The Japanese Society of Medical Oncology Annual Meeting; 2013\/08\/29\u20132013\/08\/31. p. O1\u201347. [Japanese]."},{"key":"3849_CR4","unstructured":"The Committee for Revision of Clinical Guidelines for Pancreatic Cancer of the Japan Pancreas Society. The 2019 revision of the Clinical Practice Guidelines for pancreatic cancer; 2019. [Japanese]. https:\/\/www.suizou.org\/pdf\/pancreatic_cancer_cpg-2019.pdf"},{"key":"3849_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/jhbp.870","volume":"28","author":"M Nagino","year":"2019","unstructured":"Nagino M, Hirano S, Yoshitomi H, Aoki T, Uesaka K, Unno M, et al. Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition. J Hepatobiliary Pancreat Sci. 2019;28:26\u201354.","journal-title":"J Hepatobiliary Pancreat Sci."},{"key":"3849_CR6","doi-asserted-by":"publisher","first-page":"7459","DOI":"10.1007\/s13277-014-1995-9","volume":"35","author":"Z Huang","year":"2014","unstructured":"Huang Z, Liu F. Diagnostic value of serum carbohydrate antigen 19\u20139 in pancreatic cancer: a meta-analysis. Tumour Biol. 2014;35:7459\u201365.","journal-title":"Tumour Biol"},{"key":"3849_CR7","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.3748\/wjg.v21.i14.4323","volume":"21","author":"SB Su","year":"2015","unstructured":"Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19\u20139 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol. 2015;21:4323\u201333.","journal-title":"World J Gastroenterol"},{"key":"3849_CR8","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1158\/1078-0432.CCR-10-0248","volume":"17","author":"RE Brand","year":"2011","unstructured":"Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, et al. Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res. 2011;17:805\u201316.","journal-title":"Clin Cancer Res"},{"key":"3849_CR9","doi-asserted-by":"publisher","first-page":"e0118220","DOI":"10.1371\/journal.pone.0118220","volume":"10","author":"M Kojima","year":"2015","unstructured":"Kojima M, Sudo H, Kawauchi J, Takizawa S, Kondou S, Nobumasa H, et al. MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers. PLoS ONE. 2015;10:e0118220.","journal-title":"PLoS ONE"},{"key":"3849_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/bjc.1994.331","volume":"70","author":"S Kawa","year":"1994","unstructured":"Kawa S, Tokoo M, Hasebe O, Hayashi K, Imai H, Oguchi H, et al. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Br J Cancer. 1994;70:481\u20136.","journal-title":"Br J Cancer"},{"key":"3849_CR11","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.3748\/wjg.v10.i11.1675","volume":"10","author":"JT Jiang","year":"2004","unstructured":"Jiang JT, Wu CP, Deng HF, Lu MY, Wu J, Zhang HY, et al. Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer. World J Gastroenterol. 2004;10:1675\u20137.","journal-title":"World J Gastroenterol"},{"key":"3849_CR12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1158\/1078-0432.CCR-11-2347","volume":"18","author":"J Yu","year":"2012","unstructured":"Yu J, Li A, Hong SM, Hruban RH, Goggins M. MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res. 2012;18:981\u201392.","journal-title":"Clin Cancer Res"},{"key":"3849_CR13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.4172\/1948-5956.1000372","volume":"7","author":"S Ali","year":"2015","unstructured":"Ali S, Dubaybo H, Brand RE, Sarkar FH. Differential expression of microRNAs in tissues and plasma co-exists as a biomarker for pancreatic cancer. J Cancer Sci Ther. 2015;7:336\u201346.","journal-title":"J Cancer Sci Ther"},{"key":"3849_CR14","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nrd4140","volume":"12","author":"H Ling","year":"2013","unstructured":"Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12:847\u201365.","journal-title":"Nat Rev Drug Discov"},{"key":"3849_CR15","doi-asserted-by":"publisher","first-page":"4805270","DOI":"10.1155\/2016\/4805270","volume":"2016","author":"C Mayr","year":"2016","unstructured":"Mayr C, Beyreis M, Wagner A, Pichler M, Neureiter D, Kiesslich T. Deregulated microRNAs in biliary tract cancer: functional targets and potential biomarkers. BioMed Res Int. 2016;2016:4805270.","journal-title":"BioMed Res Int"},{"key":"3849_CR16","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3389\/fphys.2018.00685","volume":"9","author":"X Li","year":"2018","unstructured":"Li X, Gao P, Wang Y, Wang X. Blood-derived microRNAs for pancreatic cancer diagnosis: a narrative review and meta-analysis. Front Physiol. 2018;9:685.","journal-title":"Front Physiol"},{"key":"3849_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1261\/rna.7240905","volume":"11","author":"S Baskerville","year":"2005","unstructured":"Baskerville S, Bartel DP. Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA. 2005;11:241\u20137.","journal-title":"RNA"},{"key":"3849_CR18","doi-asserted-by":"publisher","first-page":"e3420","DOI":"10.1371\/journal.pone.0003420","volume":"3","author":"M Lu","year":"2008","unstructured":"Lu M, Zhang Q, Deng M, Miao J, Guo Y, Gao W, et al. An analysis of human microRNA and disease associations. PLoS ONE. 2008;3:e3420.","journal-title":"PLoS ONE"},{"key":"3849_CR19","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.18632\/oncotarget.28327","volume":"13","author":"T Miura","year":"2022","unstructured":"Miura T, Mitsunaga S, Matsuzaki J, Takizawa S, Kato K, Ochiai A, et al. Serum microRNAs as new criteria for referral to early palliative care services in treatment-na\u00efve advanced cancer patients. Oncotarget. 2022;13:1341\u20139.","journal-title":"Oncotarget"},{"key":"3849_CR20","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3389\/fgene.2019.01214","volume":"10","author":"X Niu","year":"2019","unstructured":"Niu X, Zhang J, Zhang L, Hou Y, Pu S, Chu A, et al. Weighted gene co-expression network analysis identifies critical genes in the development of heart failure after acute myocardial infarction. Front Genet. 2019;10:1214.","journal-title":"Front Genet"},{"key":"3849_CR21","first-page":"441","volume":"19","author":"L You","year":"2019","unstructured":"You L, Wang J, Zhang F, Zhang J, Tao H, Zheng X, et al. Potential four-miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co-expression analysis. Mol Med Rep. 2019;19:441\u201351.","journal-title":"Mol Med Rep"},{"key":"3849_CR22","doi-asserted-by":"publisher","first-page":"e64795","DOI":"10.1371\/journal.pone.0064795","volume":"8","author":"HH Cheng","year":"2013","unstructured":"Cheng HH, Yi HS, Kim Y, Kroh EM, Chien JW, Eaton KD, et al. Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLoS ONE. 2013;8:e64795.","journal-title":"PLoS ONE"},{"key":"3849_CR23","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1111\/cas.15309","volume":"113","author":"K Suzuki","year":"2022","unstructured":"Suzuki K, Igata H, Abe M, Yamamoto Y. small RNA based cancer classification project. Multiple cancer type classification by small RNA expression profiles with plasma samples from multiple facilities. Cancer Sci. 2022;113:2144\u201366.","journal-title":"Cancer Sci."},{"key":"3849_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/tmrv.2002.29404","volume":"16","author":"SO Sowemimo-Coker","year":"2002","unstructured":"Sowemimo-Coker SO. Red blood cell hemolysis during processing. Transfus Med Rev. 2002;16:46\u201360.","journal-title":"Transfus Med Rev"},{"key":"3849_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/cas.12880","volume":"107","author":"A Shimomura","year":"2016","unstructured":"Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J, et al. Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci. 2016;107:326\u201334.","journal-title":"Cancer Sci"},{"key":"3849_CR26","doi-asserted-by":"publisher","first-page":"e41561","DOI":"10.1371\/journal.pone.0041561","volume":"7","author":"K Wang","year":"2012","unstructured":"Wang K, Yuan Y, Cho J-H, McClarty S, Baxter D, Galas DJ. Comparing the microRNA spectrum between serum and plasma. PLoS ONE. 2012;7:e41561.","journal-title":"PLoS ONE"},{"key":"3849_CR27","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.3390\/cells9081915","volume":"9","author":"M Mussbacher","year":"2020","unstructured":"Mussbacher M, Krammer TL, Heber S, Schrottmaier WC, Zeibig S, Holthoff HP, et al. Impact of anticoagulation and sample processing on the quantification of human blood-derived microRNA signatures. Cells. 2020;9:1915.","journal-title":"Cells"},{"key":"3849_CR28","first-page":"205","volume-title":"Methods and applications of longitudinal data analysis","author":"X Liu","year":"2015","unstructured":"Liu X. Chapter 7. Special topics on linear mixed models. In: Lui X, editor. Methods and applications of longitudinal data analysis. Amsterdam: Elsevier; 2015. p. 205\u201342."},{"key":"3849_CR29","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/bjc.1991.422","volume":"64","author":"S Kawa","year":"1991","unstructured":"Kawa S, Oguchi H, Kobayashi T, Tokoo M, Furuta S, Kanai M, et al. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. Br J Cancer. 1991;64:899\u2013902.","journal-title":"Br J Cancer"},{"key":"3849_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1089\/pancan.2019.0017","volume":"6","author":"MM Shah","year":"2020","unstructured":"Shah MM, NeMoyer RE, Greco SH, Chen C, Moore DF, Grandhi MS, et al. Subcategorizing T1 staging in pancreatic adenocarcinoma predicts survival in patients undergoing resection: an analysis of the national cancer database. J Pancreat Cancer. 2020;6:64\u201372.","journal-title":"J Pancreat Cancer"},{"key":"3849_CR31","first-page":"1261","volume":"79","author":"K Hirano","year":"1987","unstructured":"Hirano K, Kawa S, Oguchi H, Kobayashi T, Yonekura H, Ogata H, et al. Loss of Lewis antigen expression on erythrocytes in some cancer patients with high serum CA19-9 levels. J Natl Cancer Inst. 1987;79:1261\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"3849_CR32","volume-title":"TNM classification of malignant tumours","author":"JD Brierley","year":"2016","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th ed. Hoboken: Wiley Blackwell; 2016.","edition":"8"},{"key":"3849_CR33","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s10620-024-08338-4","volume":"69","author":"J Huang","year":"2024","unstructured":"Huang J, Gao G, Ge Y, Liu J, Cui H, Zheng R, et al. Development of a serum-based microRNA signature for early detection of pancreatic cancer: a multicenter cohort study. Dig Dis Sci. 2024;69:1263\u201373.","journal-title":"Dig Dis Sci"},{"key":"3849_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1615\/CritRevImmunol.2023051250","volume":"44","author":"B Huang","year":"2024","unstructured":"Huang B, Xin C, Yan H, Yu Z. A machine learning method for a blood diagnostic model of pancreatic cancer based on microRNA signatures. Crit Rev Immunol. 2024;44:13\u201323.","journal-title":"Crit Rev Immunol"},{"key":"3849_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41416-023-02488-4","volume":"130","author":"W Shi","year":"2024","unstructured":"Shi W, Wartmann T, Accuffi S, Al-Madhi S, Perrakis A, Kahlert C, et al. Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer. Br J Cancer. 2024;130:125\u201334.","journal-title":"Br J Cancer"},{"key":"3849_CR36","doi-asserted-by":"publisher","first-page":"e0174237","DOI":"10.1371\/journal.pone.0174237","volume":"12","author":"A Ohashi","year":"2017","unstructured":"Ohashi A, Murata A, Cho Y, Ichinose S, Sakamaki Y, Nishio M, et al. The expression and localization of RNase and RNase inhibitor in blood cells and vascular endothelial cells in homeostasis of the vascular system. PLoS ONE. 2017;12:e0174237.","journal-title":"PLoS ONE"},{"key":"3849_CR37","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41419-018-0724-5","volume":"9","author":"B Zhou","year":"2018","unstructured":"Zhou B, Guo W, Sun C, Zhang B, Zheng F. Linc00462 promotes pancreatic cancer invasiveness through the miR-665\/TGFBR1-TGFBR2\/SMAD2\/3 pathway. Cell Death Dis. 2018;9:706.","journal-title":"Cell Death Dis"},{"key":"3849_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153903","volume":"96","author":"M Li","year":"2022","unstructured":"Li M, Cai O, Yu Y, Tan S. Paeonol inhibits the malignancy of Apatinib-resistant gastric cancer cells via LINC00665\/miR-665\/MAPK1 axis. Phytomedicine. 2022;96: 153903.","journal-title":"Phytomedicine"},{"key":"3849_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.546275","volume":"11","author":"X Lin","year":"2020","unstructured":"Lin X, Huang C, Chen Z, Wang H, Zeng Y. CircRNA_100876 is upregulated in gastric cancer (GC) and promotes the GC cells\u2019 growth, migration and invasion via miR-665\/YAP1 signaling. Front Genet. 2020;11: 546275.","journal-title":"Front Genet"},{"key":"3849_CR40","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1007\/s10620-020-06705-5","volume":"66","author":"W Liu","year":"2021","unstructured":"Liu W, Hu W, Hou K, Zhu S. Circular RNA paired-related homeobox 1 promotes gastric carcinoma cell progression via regulating MicroRNA-665\/YWHAZ axis. Dig Dis Sci. 2021;66:3842\u201353.","journal-title":"Dig Dis Sci"},{"key":"3849_CR41","doi-asserted-by":"publisher","first-page":"595585","DOI":"10.3389\/fcell.2020.595585","volume":"8","author":"J Chen","year":"2020","unstructured":"Chen J, Li X, Yang L, Li M, Zhang Y, Zhang J, et al. CircASH2L promotes ovarian cancer tumorigenesis, angiogenesis, and lymphangiogenesis by regulating the miR-665\/VEGFA axis as a competing endogenous RNA. Front Cell Dev Biol. 2020;8:595585.","journal-title":"Front Cell Dev Biol"},{"key":"3849_CR42","first-page":"2661","volume":"18","author":"J Liu","year":"2018","unstructured":"Liu J, Jiang Y, Wan Y, Zhou S, Thapa S, Cheng W. MicroRNA-665 suppresses the growth and migration of ovarian cancer cells by targeting HOXA10. Mol Med Rep. 2018;18:2661\u20138.","journal-title":"Mol Med Rep"},{"key":"3849_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.omtn.2020.08.011","volume":"22","author":"T Zhang","year":"2020","unstructured":"Zhang T, Jing B, Bai Y, Zhang Y, Yu H. Circular RNA circTMEM45A acts as the sponge of MicroRNA-665 to promote hepatocellular carcinoma progression. Mol Ther Nucleic Acids. 2020;22:285\u201397.","journal-title":"Mol Ther Nucleic Acids"},{"key":"3849_CR44","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.7150\/jca.31362","volume":"10","author":"N Bai","year":"2019","unstructured":"Bai N, Peng E, Xia F, Wang D, Li XG, Li XY. CircABCC2 regulates hepatocellular cancer progression by decoying MiR-665. J Cancer. 2019;10:3893\u20138.","journal-title":"J Cancer"},{"key":"3849_CR45","doi-asserted-by":"publisher","first-page":"e0209750","DOI":"10.1371\/journal.pone.0209750","volume":"13","author":"A Mizoguchi","year":"2018","unstructured":"Mizoguchi A, Takayama A, Arai T, Kawauchi J, Sudo H. MicroRNA-8073: tumor suppressor and potential therapeutic treatment. PLoS ONE. 2018;13:e0209750.","journal-title":"PLoS ONE"},{"key":"3849_CR46","doi-asserted-by":"publisher","first-page":"7194","DOI":"10.1158\/0008-5472.CAN-16-0714","volume":"76","author":"P Kanlikilicer","year":"2016","unstructured":"Kanlikilicer P, Rashed MH, Bayraktar R, Mitra R, Ivan C, Aslan B, et al. Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Res. 2016;76:7194\u2013207.","journal-title":"Cancer Res"}],"updated-by":[{"DOI":"10.1186\/s12916-025-04079-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000}}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03849-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-03849-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03849-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T03:02:31Z","timestamp":1744858951000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-03849-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3849"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-03849-x","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"1 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12916-025-04079-x","URL":"https:\/\/doi.org\/10.1186\/s12916-025-04079-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This prospective observational study was approved by the ethics review committee of the National Cancer Center Hospital East and National Cancer Center Hospital (approval no. 2016\u2013049, 2020\u2013449) and the institutional review boards of collaborating institutions. The study for time-course effects was approved by the Human Tissue Samples Ethics Committee for R&D of Toray Industries, Inc. (HC2017-10, HC2021-3, and HC2021-18). All the studies complied with the principles of the Declaration of Helsinki and the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.M. received honoraria and grants from Toray Industries, Inc., and grants from the Japan Agency for Medical Research and Development (AMED) under Grant Numbers 15ck0106027h0002 and 16ck106027h0003 during the submitted work, as well as research funding from Ajinomoto Co., Inc., PFDeNA Co., Ltd., and Mitsui Chemicals Inc. outside the submitted work. M.I. received research funding from Astellas Pharma Inc., Nihon Servier Co., Ltd., and Novartis Pharma K.K. and received honoraria from Guardant Health Japan Corp., Nihon Servier Co., Ltd., Taiho Pharmaceutical Co., Ltd., M.S.D. K.K., NIPPON KAYAKU Co., Ltd., Yakult Honsha Co., Ltd., Boehringer Ingelheim GmbH, D.F.P. (Delta Fly Pharma) Inc., Merus N.V., Invitae Corp., and Novartis Pharma K.K. outside the submitted work. M.U. received grants from Toray Industries, Inc., during the submitted work, as well as research funding from Taiho Pharmaceutical Co., Ltd., AstraZeneca K.K., M.S.D. K.K., Nihon Servier Co., Ltd., Ono Pharmaceutical Co., Ltd., Incyte Biosciences Japan G.K., Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, Eisai Co., Ltd., Novartis Pharma K.K., Astellas Pharma Inc., J-pharma Co., Ltd., DFP (Delta Fly Pharma) Inc., Novocure GmbH, and Chiome Bioscience Inc. and honoraria from Taiho Pharmaceutical Co., Ltd., AstraZeneca K.K., Yakult Honsha Co., Ltd., M.S.D. K.K., Nihon Servier Co., Ltd., Ono Pharmaceutical Co., Ltd., Incyte Biosciences Japan G.K., Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, J-pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Novartis Pharma K.K. outside the submitted work. K.H2. received honoraria and research funding from Toray Industries, Inc., during the submitted work. K.T. received research funding from Toray Industries, Inc., during the submitted work, received research funding from Hitachi High-Tech Corporation and H.U. Group Research Institute G.K., and holds a patent with H.U. Group Research Institute G.K. outside the submitted work. M.T., I.M., T.K., H.Y., H.I1, H.I2, E.H., K.N., M.N., and A.O. received research funding from Toray Industries, Inc., during the submitted work. H.S. is an employee of Toray Industries, Inc., and received grants from AMED under grant numbers 15ck0106027h0002 and 16ck106027h0003 during the submitted work. S.T. is an employee of Toray Industries, Inc., and received grants from AMED under grant numbers 15ck0106027h0002 and 16ck106027h0003 during the submitted work. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}